Fighting the Drug Resistance Roadblock

March 15, 2016, noon

Author: Susan G. Komen

Drug, or treatment, resistance is a common problem for women with breast cancer. For some, treatment works initially, but

then gradually becomes ineffective as the tumor finds a way to evade the therapy. Researchers have long been studying

how to overcome treatment resistance, which is key to reducing breast cancer deaths. In breakthrough studies, Komen-funded scientists

have not only discovered a way that treatment resistance can develop, but also a potential way to prevent it.


Komen Scholar Dr. Ramon Parsons at The Icahn School of Medicine at Mount Sinai, and Komen-funded investigator Dr. Gary Johnson

at The University of North Carolina School of Medicine, have both independently discovered a potential combination therapy, using a class of drugs called BET

bromodomain inhibitors, which can overcome resistance to some therapies.


The Therapy Detour

Breast cancer cells depend on specific proteins and “pathways” to grow and survive. Treatments that target these proteins and pathways

can reduce the growth of cancer cells and temporarily stop the spread of the disease. But breast cancer cells are clever.

They eventually learn to outwit the drug and begin growing again, often by using other proteins and pathways.


Cancer Cell Traffic Jam

There are many different cell pathways involved in treatment resistance. Drs. Parsons and Johnson study different pathways, but they are both

looking at the same group of proteins these pathways have in common. Rather than using drugs against individual proteins in each

pathway, they decided to target a “master switch,” a family of proteins called BET bromodomain proteins that control many

different growth pathways. Researchers believe that drugs that block BET proteins should also block several growth pathways

at once and prevent the tumor from finding a detour.


Dr. Johnson is testing compounds that inhibit the BET proteins in a novel combination therapy to treat HER2-positive breast cancer.

Therapies that target HER2, like lapatinib, initially work well for some patients, but they eventually develop resistance. In a collaboration of 20 University of North

Carolina researchers, Johnson showed for the first time that a BET bromodomain inhibitor could prevent the onset of resistance to drugs such

as lapatinib in breast cancer cells. Johnson’s team tested several BET inhibitors, including one currently in clinical trials to treat blood cancers and a

specific type of leukemia.


"Breast cancer cells can learn to adapt so that they become resistant to treatment. Komen funding made it possible for us to

design a method to make tumor cells sensitive to treatment. Using this discovery, our goal is to make treatments durable and lasting for breast."


Pathways can be thought of as roads, and proteins as traffic signs along the road. Cells must pass through the signs to

continue along the pathway. If the cell hits a roadblock (like a therapy that targets the protein), it cannot continue down that

pathway. But eventually the cancer cell finds a detour around the roadblock by using another pathway, and continues to

grow again.